| Nusinersen versus sham control in infantile-onset spinal muscular atrophy RS Finkel, E Mercuri, BT Darras, AM Connolly, NL Kuntz, J Kirschner, ... New England Journal of Medicine 377 (18), 1723-1732, 2017 | 2083 | 2017 |
| Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy. FRS Mercuri E, Darras BT, Chiriboga CA, Day JW, Campbell C, Connolly AM ... New England Journal of Medicine 378 (7), 625-635, 2018 | 1296 | 2018 |
| Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study T Voit, H Topaloglu, V Straub, F Muntoni, N Deconinck, G Campion, ... The Lancet Neurology 13 (10), 987-996, 2014 | 379 | 2014 |
| Risdiplam in type 1 spinal muscular atrophy G Baranello, BT Darras, JW Day, N Deconinck, A Klein, R Masson, ... New England Journal of Medicine 384 (10), 915-923, 2021 | 329 | 2021 |
| Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin Y Allenbach, L Drouot, A Rigolet, JL Charuel, F Jouen, NB Romero, ... Medicine 93 (3), 150-157, 2014 | 322 | 2014 |
| Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy DE Frank, FJ Schnell, C Akana, SH El-Husayni, CA Desjardins, J Morgan, ... Neurology 94 (21), e2270-e2282, 2020 | 279 | 2020 |
| Sexual health care in persons with intellectual disabilities L Servais Mental retardation and developmental disabilities research reviews 12 (1), 48-56, 2006 | 276 | 2006 |
| Development of the P erformance of the U pper L imb module for D uchenne muscular dystrophy A Mayhew, ES Mazzone, M Eagle, T Duong, M Ash, V Decostre, ... Developmental Medicine & Child Neurology 55 (11), 1038-1045, 2013 | 237 | 2013 |
| Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy C Le Guiner, L Servais, M Montus, T Larcher, B Fraysse, S Moullec, ... Nature communications 8 (1), 16105, 2017 | 233 | 2017 |
| Clinical evidence supporting early treatment of patients with spinal muscular atrophy: current perspectives T Dangouloff, L Servais Therapeutics and clinical risk management, 1153-1161, 2019 | 203 | 2019 |
| Risdiplam-treated infants with type 1 spinal muscular atrophy versus historical controls BT Darras, R Masson, M Mazurkiewicz-Bełdzińska, K Rose, H Xiong, ... New England Journal of Medicine 385 (5), 427-435, 2021 | 198 | 2021 |
| Nusinersen treatment of spinal muscular atrophy: current knowledge and existing gaps T Gidaro, L Servais Developmental Medicine & Child Neurology 61 (1), 19-24, 2019 | 187 | 2019 |
| Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial KA Strauss, MA Farrar, F Muntoni, K Saito, JR Mendell, L Servais, ... Nature medicine 28 (7), 1381-1389, 2022 | 176 | 2022 |
| Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial E Mercuri, F Muntoni, G Baranello, R Masson, O Boespflug-Tanguy, ... The Lancet Neurology 20 (10), 832-841, 2021 | 167 | 2021 |
| Morbidity and mortality from ataxia-telangiectasia are associated with ATM genotype. CN Investigators. J Allergy Clin Immunol. 128 (2), 382-9, 2011 | 159 | 2011 |
| Aminopyridines correct early dysfunction and delay neurodegeneration in a mouse model of spinocerebellar ataxia type 1 R Hourez, L Servais, D Orduz, D Gall, I Millard, A de Kerchove d'Exaerde, ... Journal of Neuroscience 31 (33), 11795-11807, 2011 | 158 | 2011 |
| Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled … E Mercuri, N Deconinck, ES Mazzone, A Nascimento, M Oskoui, K Saito, ... The Lancet Neurology 21 (1), 42-52, 2022 | 154 | 2022 |
| Prospective and longitudinal natural history study of patients with Type 2 and 3 spinal muscular atrophy: Baseline data NatHis-SMA study A Chabanon, AM Seferian, A Daron, Y Péréon, C Cances, C Vuillerot, ... PLoS One 13 (7), e0201004, 2018 | 152 | 2018 |
| Newborn screening programs for spinal muscular atrophy worldwide: Where we stand and where to go T Dangouloff, E Vrščaj, L Servais, D Osredkar, T Adoukonou, O Aryani, ... Neuromuscular Disorders 31 (6), 574-582, 2021 | 147 | 2021 |
| Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial KA Strauss, MA Farrar, F Muntoni, K Saito, JR Mendell, L Servais, ... Nature medicine 28 (7), 1390-1397, 2022 | 140 | 2022 |
